Skip to main content
. 2018 Oct 5;13(10):e0205454. doi: 10.1371/journal.pone.0205454

Table 2. Baseline characteristics in the subjects (n = 1045) with and without atrial fibrillation (AF) in the follow-up.

No AF (n = 940) AF (n = 105) p-value
Age (years) 51 ± 6 54 ± 5 <0.001
Sex (male), n (%) 455 (48%) 65 (62%) 0.009
Study group (hypertensives), n (%) 460 (49%) 59 (56%) 0.159
Diabetics, n (%) 92 (10%) 14 (13%) 0.254
Coronary artery disease, n (%) 92 (10%) 26 (25%) <0.001
Systolic blood pressure (mmHg) 147 ± 22 156 ± 23 <0.001
Diastolic blood pressure (mmHg) 89 ±12 91 ± 14 0.138
Body mass index (kg/m2) 27.6 ± 5 29.0 ± 5 0.003
Waist circumference (cm) 90 ± 13 95 ± 13 <0.001
Fasting glucose (mmol/l) 4.7 ± 1.5 4.9 ± 1.3 0.434
ANP (pmol/l) 273 ± 153 350 ± 256 <0.001
Total cholesterol (mmol/l) 5.7 ± 1.1 5.7 ± 1.0 0.619
HDL-cholesterol (mmol/l) 1.4 ± 0.4 1.3 ± 0.4 0.021
LDL-cholesterol (mmol/l) 3.6 ± 1.0 3.6 ± 0.9 0.477
Triglycerides (mmol/l) 1.6 ± 1.0 1.8 ± 1.1 0.064
hs-CRP (mg/l) 3.8 ± 7.6 3.9 ± 6.0 0.868
ALT (U/l) 31 ± 23 37 ± 22 0.012
Creatinine (μmol/l) 82 ± 15 91 ± 89 0.007
Alcohol (g/week) 59 ± 86 79 ± 117 0.033
Smoking (pack years) 10 ± 14 13 ± 17 0.020
IMT (mm) 0.87 ± 0.18 0.92 ± 0.21 0.007
Left atrial diameter (mm) 39 ± 5 41 ± 5 <0.001
β-blockers, n (%) 247 (26%) 39 (37%) 0.018
Calcium blockers, n (%) 113 (12%) 15 (14%) 0.502
ACE-inhibitors, n (%) 174 (19%) 30 (29%) 0.014
Diuretic drugs, n (%) 153 (16%) 19 (18%) 0.634
Digitalis, n (%) 12 (1%) 12 (11%) <0.001
Lipid lowering drug, n (%) 27 (3%) 3 (3%) 0.993
Aspirin, n (%) 47 (5%) 11 (10%) 0.020

The values are means ± SD, absolute numbers with percentages or percentages alone. The medication data is expressed as number of subjects and percentages. Differences were tested by the ANOVA test for continuous variables and Pearson Chi-Squared test for categorical variables. ANP, atrial natriuretic peptide; hs-CRP, high-sensitive C-reactive protein; ALT, alanine aminotransferase; IMT, intima-media thickness; ACE, angiotensin converting enzyme.